Send to

Choose Destination
  • PMID: 28257302 was deleted because it is a duplicate of PMID: 28422792
Curr Opin HIV AIDS. 2017 May;12(3):285-293. doi: 10.1097/COH.0000000000000368.

Progress in HIV-1 antibody research using humanized mice.

Author information

aInstitute of Virology, University Hospital Cologne bLaboratory of Experimental Immunology, Center for Molecular Medicine Cologne (CMMC), University of Cologne cDepartment I of Internal Medicine, University Hospital Cologne dGerman Center for Infection Research, partner site Bonn-Cologne, Cologne, Germany.



Recent discoveries of highly potent broadly HIV-1 neutralizing antibodies provide new opportunities to successfully prevent, treat, and potentially cure HIV-1 infection. To test their activity in vivo, humanized mice have been shown to be a powerful model and were used to investigate antibody-mediated prevention and therapy approaches. In this review, we will summarize recent findings in humanized mice that have informed on the potential use of broadly neutralizing antibodies targeting HIV-1 in humans.


Humanized mouse models have been used to demonstrate the antiviral efficacy of HIV-1 neutralizing antibodies in vivo. It has been shown that a combination of antibodies can suppress viremia below the limit of detection and targets the HIV-1 reservoir. Moreover, passively administered antibodies and vector-mediated antibody production protect humanized mice from HIV-1 infection. Finally, immunization studies in knock-in/transgenic mice carrying human antibody gene segments have informed on potential vaccination strategies to induce broad and potent HIV-1 neutralizing antibodies.


Humanized mouse models are of great value for HIV-1 research. They represent a highly versatile in vivo system to investigate novel approaches for HIV-1 prevention and therapy and expedite the critical translation from basic findings to clinical application.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center